Dear Molecular Imaging Insider,
A fruitful and active area of research right now concerns the clinical applications for which PET/MRI may be advantageous in breast cancer.
Two studies presented at the European Society of Breast Imaging (EUSOBI) annual meeting caught our attention in this area. The first is about evaluating patients treated with neoadjuvant chemo(targeted) therapy, while the second focuses on PET/MRI as a technique for preoperative axillary staging in early breast cancer patients. You can read more in today’s top story.
Meanwhile, positron emission mammography, a high-resolution tomographic method for molecular imaging of positron-emitting isotopes, is proving a useful technique in the presurgical assessment of invasive lobular carcinoma.
The recently established EANM Journal aims to become the leading global publication for nuclear medicine and allied sciences. It has just published an important article on early perfusion imaging used as part of a dual-phase protocol in amyloid-PET studies.
Will F-18 prostate-specific membrane antigen (PSMA) PET/CT replace F-18 sodium fluoride (NaF) PET/CT in patients with prostate cancer? Danish researchers have found that doing this can improve treatment decisions for men with newly diagnosed prostate cancer.
The integration of radiological images, histopathological slides, and molecular profiles presents a huge challenge, but it also offers an opportunity to develop standardized, interoperable platforms that unify diagnostic data streams. Two experts are convinced that the merger of radiology and pathology, along with the implementation of AI, can facilitate this process.
These news stories are just a sample of the extensive material we’ve posted over the last few weeks in the Molecular Imaging Content Area.
Philip Ward
Editor in Chief
AuntMinnieEurope.com
